OUR UNIQUE CONDITIONALLY ACTIVATED siRNA (CASi) PLATFORM COMBINES ADVANTAGEOUS PROPERTIES OF SINGLE AND DOUBLE-STRANDED RNA IN A SINGLE MOLECULE, ALLOWING FOR CELL-SELECTIVE RNAi ACTIVITY, EFFICIENT SELF-DELIVERY AND UPTAKE, POTENCY AND DURABLE GENE KNOCKDOWN.
Switch’s Conditionally Activated siRNA (CASi), developed at Caltech, Harvard Medical School and City of Hope, combines the best attributes of antisense oligonucleotides (ASO) and siRNAs.
THE CASi CONSTRUCT
EACH CASi MOLECULE EMPLOYS A SMALL INTERFERING (siRNA) STRUCTURE WITH ADDED EXTENSIONS TO DOCK TO A UNIQUE RNA SENSOR.
The combination of a unique mechanism for cell selectivity and effective, self-delivery, enables new avenues for next generation RNAi therapy.